Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) Enterprise Value (2024 - 2025)

Kairos Pharma's Enterprise Value history spans 2 years, with the latest figure at -$4.5 million for Q4 2025.

  • For Q4 2025, Enterprise Value changed N/A year-over-year to -$4.5 million; the TTM value through Dec 2025 reached -$4.5 million, changed N/A, while the annual FY2025 figure was -$4.5 million, N/A changed from the prior year.
  • Enterprise Value reached -$4.5 million in Q4 2025 per KAPA's latest filing, down from -$3.0 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$3.0 million in Q2 2025 to a low of -$4.5 million in Q4 2025.